CureDuchenne is pleased to see the positive preliminary data from Capricor Therapeutics on their HOPE clinical trial in Duchenne muscular dystrophy. CureDuchenne Ventures helped fund this clinical trial to address […]
LOS ANGELES, April 25, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced positive top-line results […]
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution […]
April 20, 2017 Dear Duchenne Community, Today we announced that we have completed our acquisition of Emflaza™ (deflazacort), the first FDA-approved, anti-inflammatory therapy for Duchenne Muscular Dystrophy (DMD) patients […]
Using CRISPR-Cpf1 gene editing, researchers have fixed mutations that cause a form of muscular dystrophy in cultured human cardiomyocytes and a mouse model. By Anna Azvolinsky | April 12, 2017 […]
NVC Consulting, a market research firm, is looking for patients and caregivers to participate in a paid market research study regarding the treatment of patients with Duchenne Muscular Dystrophy on […]
Physical Therapist Elina Gonzalez’s intuition has been a driving force in her career. During one of her early cases, a child presented signs of muscle weakness and underdevelopment, but remained […]
NEWPORT BEACH, Calif., April 5, 2017 – CureDuchenne, the leading nonprofit focused on finding a cure for Duchenne muscular dystrophy, is proud to sponsor SB 643 (Pan) which passed the […]
(CureDuchenne letter to Anthem dated March 14) CureDuchenne believes that all those with Duchenne that have a treatment option available to them should have access to the drug. Our heart […]
